Impact of the use of nephrotoxic drugs in critically ill pediatric patients

**ORIGINAL ARTICLE**

**INTRODUCTION**

Acute kidney injury (AKI) is a complication often found in patients admitted to the pediatric intensive care unit (ICU) and is characterized by a reduced glomerular filtration rate and/or urine output.\(^1,2\) The main complications related to this disorder are increased fluid overload, reduced excretion of nitrogen compounds, and fluid and electrolyte and acid-base disorders.\(^3,4\) In addition, patients have longer hospital stays and a higher risk of death.\(^3,4\)

Drug nephrotoxicity is one of the main causes of AKI in critically ill children.\(^5,6\) There are multiple mechanisms of renal injury, and the most prevalent are those that cause a reduction in the glomerular filtration rate, acute tubular necrosis, acute interstitial nephritis and renal tubular obstruction.\(^7\)

Studies in the pediatric ICU show an association between the use of nephrotoxic drugs (NTDs) and AKI. Gupta et al., in a study involving 536...
patients, found that 76% of children with AKI used NTDs, and this association was statistically significant (p = 0.007). Similar results were found in the studies by Freire et al. and Bresolin et al., in which 62% and 39% of patients, respectively, who developed AKI used NTDs, with significant results.\(^{9,10}\) The main NTDs studied were vancomycin, furosemide, aminoglycosides, nonsteroidal anti-inflammatory drugs, amphotericin and antiviral drugs.\(^{5,6,11,12}\)

Despite the importance of the topic in intensive care, few studies have evaluated the incidence and impact of the concomitant use of two or more NTDs in critically ill pediatric patients. McKamy et al. observed that patients who used vancomycin combined with furosemide had a higher risk of AKI than those who used vancomycin alone (p < 0.001).\(^{13}\) Other studies reinforce this hypothesis.\(^{14}\)

The objective of this study was to evaluate the association between the use of NTDs and AKI in critically ill pediatric patients.

**METHODS**

This is a retrospective cohort study conducted with all patients admitted to the pediatric, clinical and surgical ICU of a 22-bed reference pediatric hospital in 2017. The data were extracted from the electronic medical records of the unit. The study was approved by the Research Ethics Committee of the Hospital Infantil Pequeno Príncipe (CAAE: 98429818.5.0000.0097), according to resolution 466/12. The free and informed consent term was waived in the study.

The inclusion criteria were length of stay in the pediatric ICU longer than 48 hours and age between 1 month and 14 years. The exclusion criteria were a history of chronic kidney disease, urogenital disease or kidney transplant; presence of AKI on admission to the pediatric ICU; congenital or acquired heart disease; chronic use of NTDs; creatine phosphokinase ≥ 1,000 U/L; leukocytes ≥ 50,000/mm\(^3\) and/or admission for induction chemotherapy; readmission to the pediatric ICU during the same hospital stay; a lack of baseline serum creatinine data; and absence of serum creatinine levels during the pediatric ICU stay.

Nephrotoxic drug is defined as a drug that has the potential to cause AKI as an adverse event\(^{15}\) (Table 1).

| Nephrotoxic drugs |          |
|-------------------|----------|
| Acyclovir         | Gentamicin |
| Amikacin          | Ibuprofen |
| Amphotericinβ     | Ifofarimide |
| Captopril         | Lithium   |
| Carboamino        | Mesalazine |
| Cyclosporine      | Methotrexate |
| Cidofovir         | Sirolimus |
| Ciclosporin       | Sulfasalazine |
| Dapsone           | Tacrolimus |
| Enalapril         | Tobramycin |
| Foscarnet         | Topiramate |
| Furosemide        | Trometamol |
| Ganciclovir       | Vancomycin |

Acute kidney injury was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) classification.\(^{1}\) Patients with a creatinine (Cr) increase < 0.3mg/dL or < 1.5-fold compared to the baseline serum level were classified as without AKI; those with a Cr increase ≥ 0.3mg/dL or between 1.5- and 1.9-fold compared to baseline Cr were classified as stage 1; those with a 2- to 2.9-fold increase in Cr were classified as stage 2; and those with a ≥ 3-fold increase in Cr were classified as stage 3. In this study, urine output was not used to classify the patient as having AKI because drug nephrotoxicity is characterized as nonoliguric.\(^{15}\) The baseline Cr was the Cr value within the normal range that the patient had in the 3 months before admission to the pediatric ICU according to the unit’s electronic database.

The variables of interest included age, sex, reason for admission, length of hospital stay, Pediatric Risk of Mortality 2 (PRISM 2) score, vasoactive drug use (VAD), presence of AKI, AKI stages, timepoint of the stay at which AKI developed, use of NTDs alone or in combination, duration of NTD use, time between the use of NTDs and the onset of AKI and time between AKI and normalization of renal function or death.

For statistical analysis, the software Epi Info™ Windows 7.2 and Microsoft® Office Excel 2017 were used. For qualitative variables, frequencies and proportions
were calculated. For quantitative variables, we evaluated the mean, standard deviation, median, quartiles and maximum and minimum values. Bivariate analyses were performed using the chi-square test, Fisher’s exact test and Pearson’s correlation coefficient (r), with the calculation of odds ratio (ORs) and 95% confidence intervals (95%CIs) a significance level of 5% (p ≤ 0.05). Logistic regression was used to rule out possible confounders in the association between the use of NTDs and AKI.

RESULTS

The population admitted to the pediatric ICU during the study period comprised 710 patients; 484 children were excluded, resulting in a sample of 226 patients. Among the excluded patients, 219 patients had a length of stay of less than 48 hours; 77 had AKI on admission; 69 were older than 14 years; 46 had congenital or acquired heart disease; 21 presented with uropathy; 19 had chronic kidney disease; 19 did not have all the data necessary to calculate the variables of interest; nine chronically used NTDs; three were kidney transplant recipients; one patient had rhabdomyolysis; and one had a risk of tumor lysis syndrome.

The sample was predominantly male (54.4%), with a mean age of 3.5 years and a mean baseline Cr of 0.24mg/dL. Hemodynamic shock was the reason for hospitalization in 10.2% (23) of patients, and VAD was used in 17.6% (40) of the sample. The mean length of stay in the pediatric ICU was 10 days, with a mean expected mortality rate at admission of 3% according to PRISM 2, and 7.5% (17) progressed to death (Tables 2 and 3).

Among the subjects, 42% (96) developed AKI. Of these, 57.2% (55) had stage 1 disease, 28.2% (27) had stage 2 disease, and 14.6% (14) had stage 3 disease. The variables that were associated with renal dysfunction were ICU admission due to hemodynamic shock (p < 0.001), PRISM 2 ≥ 10% (p = 0.037), use of VAD (p < 0.001) and use of NTDs alone or in combination (p < 0.001) (Table 4).

A total of 37.1% (84) of the sample used one or more NTDs. Of these, 73.8% (62) used only one NTD, 21.5% (18) used two combined NTDs and 4.7% (4) used three NTDs, so that these medications were prescribed 110 times among patients in the sample. In decreasing order of frequency, 18.5% (42) of the patients used furosemide, 14.1% (32) used vancomycin, 7% (16) used acyclovir, 2.6% (6) used nonsteroidal anti-inflammatory drugs, 2.2% (5) used ganciclovir, 2.2% (5) used gentamicin, and 1.7% (4) used amikacin (Table 5). The mean number of days between the use of NTD and the onset of AKI was 3.6 days. The drugs that were associated with AKI when used alone were acyclovir (p < 0.001), vancomycin (p < 0.001), ganciclovir (p = 0.008) and furosemide (p < 0.001). When we analyzed the association of these drugs with AKI by means of logistic regression adjusted for admission due to hemodynamic shock, PRISM 2 ≥ 10% and VAD use, the only drug that was identified as an independent marker of AKI was acyclovir (OR = 15.3; 95%CI 4.1 - 57; p < 0.001).

The most commonly used combination was furosemide + vancomycin (13), followed by furosemide + acyclovir (4). When we analyzed the association of the use of two or more NTDs with AKI by means of logistic regression adjusted for admission due to hemodynamic shock, PRISM 2 ≥ 10% and VAD use, we found that using ≥ 2 NTDs concomitantly was an independent marker of AKI (p < 0.001) (Table 6). In addition, hemodynamic shock (OR = 3.6; 95%CI 1.03 - 13; p = 0.04) and VAD use (OR = 12.8; 95%CI 5.1 - 31.8; p < 0.001) were also classified as independent AKI markers.

The mean duration of NTD use in patients without AKI was 8 days (± 4.9). Patients with stage 1 AKI had a mean duration of use of 12 days (± 12.2), and those with stage 2 or 3 AKI had a mean duration of use of 13.1 days (± 8.8). The correlation analysis between the time of use of NTD and AKI stage showed r = 0.21 (p = 0.83).

Regarding renal function recovery time, patients who developed stage 1 AKI required a mean of 3.1 days (± 3.6) for Cr to normalize; patients with stage 2 AKI recovered

| Variables | n (%) |
|-----------|-------|
| Sex male | 123 (54.4) |
| Age (years) | 2 (0 - 6) |
| Baseline creatinine | 0.24 ± 0.08 |
| Reason for admission | |
| Respiratory failure | 84 (37.2) |
| Monitoring | 78 (34.5) |
| Reduced level of consciousness | 41 (18.1) |
| Hemodynamic shock | 23 (10.2) |
| PRISM 2 | 1.5 (0.8 - 3.4) |
| Use of vasoactive drugs | 40 (17.6) |
| Use of NTDs | 84 (37.1) |
| AKI | 96 (42.4) |
| Stage 1 | 55 (57.2) |
| Stage 2 | 27 (28.2) |
| Stage 3 | 14 (14.6) |
| Duration of NTD use (days) | 10 (4 - 14) |
| Time between NTD and the onset AKI (days) | 2 (1 - 5) |
| Time between AKI and creatinine normalization (days) | 2 (1 - 6.5) |
| Length of stay in the pediatric ICU (days) | 6 (4 - 11) |
| Death | 17 (7.5) |

PRISM 2 - Pediatric Risk of Mortality 2; AKI - acute kidney injury; NTD - nephrotoxic drug; ICU - intensive care unit. Results are expressed as n (%), median (p25% - p75%) or mean ± standard deviation.
### Table 3 - Comparison of patients regarding the use of nephrotoxic drugs

| Variable                  | Yes          | No           | Total | OR  | 95%CI       | p value |
|---------------------------|--------------|--------------|-------|-----|-------------|---------|
| **Age**                   |              |              |       |     |             |         |
| Infant                    | 38 (45.3)    | 59 (41.6)    | 97    | 1   | –           | –       |
| Preschool-age             | 23 (27.4)    | 37 (28)      | 60    | 1.00| 0.52 - 1.95 | 0.98    |
| School age                | 11 (13.1)    | 32 (22.5)    | 43    | 0.56| 0.25 - 1.24 | 0.15    |
| Adolescent                | 12 (14.2)    | 14 (9.9)     | 26    | 1.39| 0.58 - 3.32 | 0.46    |
| **Sex**                   |              |              |       |     |             |         |
| Male                      | 42 (50)      | 81 (57)      | 123   | 0.75| 0.43 - 1.29 | 0.3     |
| Female                    | 42 (50)      | 61 (43)      | 103   | 1   | –           | –       |
| **Reason for admission**  |              |              |       |     |             |         |
| Monitoring                | 28 (33.3)    | 50 (35.3)    | 78    | 1   | –           | –       |
| Respiratory failure       | 27 (32.1)    | 57 (40)      | 84    | 0.89| 0.46 - 1.72 | 0.74    |
| Hemodynamic shock         | 14 (16.7)    | 9 (6.4)      | 23    | 2.91| 1.12 - 7.60 | 0.02    |
| Decreased consciousness   | 15 (17.9)    | 26 (18.3)    | 41    | 1.08| 0.49 - 2.39 | 0.83    |
| **PRISM 2**               |              |              |       |     |             |         |
| ≥ 10%                     | 6 (7.1)      | 5 (3.5)      | 11    | 2.1 | 0.62 - 7.13 | 0.22    |
| < 10%                     | 78 (92.9)    | 137 (96.5)   | 215   | 1   | –           | –       |
| **Vasoactive drug**       |              |              |       |     |             |         |
| Yes                       | 29 (34.5)    | 11 (7.7)     | 40    | 6.27| 2.93 - 13.45| < 0.001 |
| No                        | 55 (65.5)    | 131 (92.3)   | 186   | 1   | –           | –       |
| **Length of stay (days)** |              |              |       |     |             |         |
| ≥ 7                       | 52 (62)      | 54 (38)      | 106   | 2.64| 1.51 - 4.61 | < 0.001 |
| < 7                       | 32 (38)      | 88 (62)      | 120   | 1   | –           | –       |
| **Death**                 |              |              |       |     |             |         |
| Yes                       | 12 (14.3)    | 5 (3.5)      | 17    | 4.56| 1.54 - 13.46| 0.003   |
| No                        | 72 (85.7)    | 137 (96.5)   | 209   | 1   | –           | –       |
| **Total**                 | 84           | 142          | 226   |     |             |         |

NTDs - nephrotoxic drugs; OR - odds ratio; 95%CI - 95% confidence interval; PRISM 2 - Pediatric Risk of Mortality 2. Results are expressed as n (%) when not otherwise indicated.

### Table 4 - Association of clinical and demographic variables with acute kidney injury in critically ill pediatric patients

| Variable                  | Yes          | No           | Total | OR  | 95%CI       | p value |
|---------------------------|--------------|--------------|-------|-----|-------------|---------|
| **Age**                   |              |              |       |     |             |         |
| Infant                    | 50 (51.5)    | 47 (48.5)    | 97    | 1   | –           | –       |
| Preschool-age             | 26 (43.3)    | 34 (56.7)    | 60    | 1.17| 0.52 - 2.66 | 0.69    |
| School-age                | 12 (38)      | 31 (72)      | 43    | 1.24| 0.50 - 3.06 | 0.63    |
| Adolescent                | 8 (30.7)     | 18 (69.3)    | 26    | 0.61| 0.17 - 2.25 | 0.46    |
| **Sex**                   |              |              |       |     |             |         |
| Male                      | 50 (40.6)    | 73 (59.4)    | 123   | 0.84| 0.49 - 1.44 | 0.54    |
| Female                    | 46 (44.6)    | 57 (55.4)    | 103   | 1   | –           | –       |
| **Reason for admission**  |              |              |       |     |             |         |
| Monitoring                | 26 (33.3)    | 52 (66.7)    | 78    | 1   | –           | –       |
| Respiratory failure       | 32 (38)      | 52 (62)      | 84    | 1.32| 0.5 - 3.46  | 0.57    |
| Hemodynamic shock         | 16 (69.5)    | 7 (30.5)     | 23    | 9.48| 3.16 - 28   | < 0.001 |
| Decreased consciousness   | 22 (53.6)    | 19 (46.4)    | 41    | 2.80| 1.01 - 7.76 | 0.046   |
| **PRISM 2**               |              |              |       |     |             |         |
| ≥ 10%                     | 8 (72.7)     | 3 (27.3)     | 11    | 3.84| 1 - 14.91   | 0.037   |
| < 10%                     | 88 (41)      | 127 (59)     | 215   | 1   | –           | –       |
| **Vasoactive drug**       |              |              |       |     |             |         |
| Yes                       | 31 (77.5)    | 9 (22.5)     | 40    | 6.41| 2.87 - 14.28| < 0.001 |
| No                        | 65 (35)      | 121 (65)     | 186   | 1   | –           | –       |
| Use ≥ 1 DNT               |              |              |       |     |             |         |
| Yes                       | 57 (67.8)    | 27 (32.2)    | 84    | 5.57| 3.07 - 10.03| < 0.001 |
| No                        | 39 (27.5)    | 103 (72.5)   | 142   | 1   | –           | –       |
| Use ≥ 2 DNT               |              |              |       |     |             |         |
| Yes                       | 21 (95.5)    | 1 (4.5)      | 22    | 36.12| 4.76 - 273.98| < 0.001 |
| No                        | 75 (36.7)    | 129 (63.3)   | 204   | 1   | –           | –       |
| **Total**                 | 96           | 130          | 226   |     |             |         |

AKI - acute kidney injury; OR - odds ratio; 95% CI - confidence interval; PRISM 2 - Pediatric Risk of Mortality 2; NTDs - nephrotoxic drugs. The results expressed as n (%) when not otherwise indicated.
Table 5 - Analysis of the duration of use of nephrotoxic drugs in the sample studied

| NTD               | Patients (N) | Mean (days) | Median (days) | SD (days) | Minimum (days) | Maximum (days) |
|-------------------|--------------|-------------|---------------|-----------|----------------|----------------|
| Acyclovir         | 16           | 11.4        | 14            | 5.1       | 2              | 21             |
| Amikacin          | 4            | 9           | 8.5           | –         | 5              | 14             |
| Anti-inflammatory*| 6            | 2.8         | 2.5           | –         | 2              | 5              |
| Furosemide        | 42           | 6           | 4             | 5.2       | 2              | 30             |
| Ganciclovir       | 5            | 13.8        | 14            | –         | 3              | 24             |
| Gentamicin        | 5            | 4           | 3             | –         | 2              | 7              |
| Vancomycin        | 32           | 11.1        | 10            | 7.2       | 2              | 40             |

NTDs - nephrotoxic drug; SD - standard deviation. *Includes ibuprofen and trometamol.

Table 6 - Multivariate logistic regression for the adjustment of possible confounders in the association between concomitant use of nephrotoxic drugs and acute kidney injury

| ≥ 2 NTDs | AKI | OR (95%CI) |
|----------|-----|------------|
| Stages 1 + 2 + 3 (reference group: without AKI) | Not adjusted | 36.1 (4.7 - 272.9) |
| | Adjusted - admission due to shock | 37 (4.8 - 281.6) |
| | Adjusted - PRISM 2 ≥ 10% | 33 (4.3 - 251.6) |
| | Adjusted - VAD | 25.1 (3.2 - 194.7) |
| | Adjusted - shock, PRISM 2 and VAD | 27.5 (3.5 - 215.5) |
| Stages 2 + 3 (reference group: stage 1 + without AKI) | Not adjusted | 11.4 (4.4 - 29.1) |
| | Adjusted - admission due to shock | 13.5 (4.9 - 37.1) |
| | Adjusted - PRISM 2 ≥ 10% | 10 (3.7 - 27) |
| | Adjusted - VAD | 6.9 (2.1 - 22) |
| | Adjusted - shock, PRISM 2 and VAD | 7.8 (2.4 - 25.9) |

NTDs - nephrotoxic drugs; AKI - acute kidney injury; OR - odds ratio; 95%CI - 95% confidence interval; PRISM 2 - Pediatric Risk of Mortality 2; VAD - vasoactive drug.

After adjustment by logistic regression, the only NTD identified as an independent marker of AKI was acyclovir, and it was used mainly for empirical treatment of meningocencephalitis caused by herpesvirus type 1. Its mechanism of injury is characterized by the formation of crystals and the obstruction of tubules, and the risk of renal dysfunction is dose dependent. Slater et al. found that ganciclovir, furosemide and gentamicin were the main drugs associated with AKI in critically ill patients (p < 0.05). The different methodological profiles used for sample selection may explain the divergence between the results, and additional, preferably prospective, studies are needed to identify the main NTDs associated with renal dysfunction in critically ill children.

When we analyzed the concomitant use of these drugs, the risk of AKI was observed to increase progressively as the number of NTDs used increased. McKamy et al., in a retrospective study conducted in a pediatric ICU, identified a 3- to 9-fold increased risk of AKI when vancomycin was used concomitantly with furosemide (p < 0.05). Our study showed similar results, and this variable was characterized as an independent marker of AKI (p < 0.001). This finding is relevant in the context of critically ill children because drug-induced renal dysfunction is potentially reversible.

In addition, studies show that after recovery from AKI, the patient has an increased risk of chronic kidney disease as a result of the development of proteinuria and hypertension and a reduced glomerular filtration rate. Therefore, prevention measures are essential to avoid short- and long-term complications, and drugs with fewer adverse effects should always be chosen when possible. Special attention should be given to critically ill children with heart disease, cancer, nephrotic syndrome and those in the neonatal period as they are usually exposed to large amounts of NTDs.

We observed that one-fifth of the children using NTDs had inadequate monitoring of renal function after discharge to the ward. Other studies show that up to 33% of patients with AKI are inadequately managed. Thus, we emphasize that serially assessing renal function for...
early identification of the problem, avoiding concomitant use of NTDs, adjusting the dose of drugs according to the estimated glomerular filtration rate and maintaining a normovolemic state are imperative measures in the management of these patients.\(^{(7)}\)

Our study had some limitations intrinsic to retrospective studies. Approximately 2.6% of the study population was excluded due to the lack of data needed to calculate the variables of interest, which may impact the result. The sample size is considered small compared to other studies in the literature; consequently, there is a greater risk of type 2 random error in the analysis of drug classes that were rarely used by patients, such as nonsteroidal anti-inflammatory drugs and aminoglycosides.\(^{(12,26)}\) Although radiocontrast agents used for imaging are considered nephrotoxic, it was not possible to identify the different types of agents and their respective osmolarities in this study, and thus, they were not included in the list of NTDs. The first author was responsible for data collection, and the use of a structured questionnaire with a systematic data storage methodology minimized the risk of bias. Finally, we chose to analyze a small group of drugs that includes the drugs that were most commonly used in the unit where the study was conducted.

**CONCLUSION**

Acyclovir alone was the drug most strongly associated with renal dysfunction in this study. In addition, concomitant use of nephrotoxic drugs was characterized as an independent marker of acute kidney injury.

To better characterize the impact of the use of nephrotoxic drugs in critically ill children, further studies on the subject are needed, and the multifactorial genesis of acute kidney injury should be considered.

It is necessary for pediatric intensivists to have knowledge of the main nephrotoxic drugs to predict, reduce or avoid damage to their patients.

**AUTHOR CONTRIBUTIONS**

J. P. Almeida: data collection, data analysis and writing of the manuscript; P. R. D. João: advisor, review and approval of the final version; L. C. Sylvestre: advisor, review and approval of the final version.

**REFERENCES**

1. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138.

2. Cleto-Yamane TL, Gomes CL, Suassuna JH, Nogueira PK. Acute kidney injury epidemiology in pediatrics. J Bras Nefrol. 2019;41(2):275-83.

3. Levi TM, Souza SP, Magalhães JS, Cavalcão MS, Cunha AL, Dantas JG, et al. Comparação dos critérios RIFLE, AKIN e KDIGO quanto à capacidade de previsão de mortalidade em pacientes graves. Rev Bras Ter Intensiva. 2013;25(4):290-6.

4. Ponce D, Zorzenon CP, Santos NY, Teixeira UA, Balbi AL. Injúria renal aguda em unidade de terapia intensiva: estudo prospectivo sobre a incidência, fatores de risco e mortalidade. Rev Bras Ter Intensiva. 2011;23(3):321-6.

5. Patzer L. Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol. 2008;23(12):2159-73.
6. Slater MB, Gruneir A, Rochon PA, Howard AW, Koren G, Parshuram CS. Identifying high-risk medications associated with acute kidney injury in critically ill patients: a pharmacoepidemiologic evaluation. Paediatr Drugs. 2017;19(1):59-67.

7. Panu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008;36(4 Suppl):S216-23.

8. Gupta S, Sengar GS, Meti PK, Lahoti A, Beniwal M, Kumawat M. Acute kidney injury in pediatric intensive care unit: incidence, risk factors, and outcome. Indian J Crit Care Med. 2016;20(9):526-9.

9. Freire KM, Bresolin NL, Farah AC, Carvalho FL, Gôes JE. Lesão renal aguda em crianças: incidência e fatores prognósticos em pacientes gravemente enfermos. Rev Bras Ter Intensiva. 2010;22(2):166-74.

10. Bresolin N, Bianchini AP, Haas CA. Pediatric acute kidney injury assessed by pRIFLE as a prognostic factor in the intensive care unit. Pediatr Nephrol. 2013;28(3):485-92.

11. Soler YA, Nieves-Plaza M, Prieto M, García-de-Jesús R, Suárez-Rivera M. Pediatric Risk, Injury, Failure, Loss, End-Stage renal disease score identifies acute kidney injury and predicts mortality in critically ill children: a prospective study. Pediatr Crit Care Med. 2013;14(4):e189-95.

12. Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. J Pediatr. 2013;162(6):1153-9.

13. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2013;162(6):1153-9.

14. Almeida JP, Valente IF, Lordelo MD. Association between pediatric Risk, Injury, Failure, Loss and End Stage Renal Disease score and mortality in a pediatric intensive care unit: a retrospective study. Rev Bras Ter Intensiva. 2018;30(4):429-35.

15. Goldstein SL, Kirkendall ES, Nguyen H, Schaffzin JK, Bucuvalas J, Bracke T, et al. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatrics. 2013;132(3):e575-87.

16. Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic medication exposure in noncritically-ill children. Clin J Am Soc Nephrol. 2011;6(4):856-63.

17. Deep A, Sagar H, Goonasekera C, Karthikeyan P, Brierley J, Douiri A. Evolution of acute kidney injury and its association with systemic hemodynamics in children with fluid-refractory septic shock. Crit Care Med. 2018;46(7):e677-83.

18. Bailey D, Phan V, Litalien C, Ducruet T, Méraouni A, Lacroix J, et al. Risk factors of acute renal failure in critically ill children: a prospective descriptive epidemiological study. Pediatr Crit Care Med. 2007;8(1):29-35.

19. Naeem B, Moozani KN, Anjum M, Imam U. Tumor lysis syndrome in pediatric acute lymphoblastic leukemia at tertiary care center. Pak J Med Sci. 2019;35(4):899-904.

20. Lim YS, Cho H, Lee ST, Lee Y. Acute kidney injury in pediatric patients with rhabdomyolysis. Korean J Pediatr. 2018;61(3):95-100.

21. Rao S, Abzug MJ, Carosone-Link P, Peterson T, Child J, Siparksy G, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. J Pediatr. 2015;166(6):1462-8.e1-4.

22. Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJ. Acute kidney injury (AKI) associated with intravenous aciclovir in adults: incidence and risk factors in clinical practice. Int J Infect Dis. 2018;74:97-9.

23. Totapally BR, Machado J, Lee H, Paredes A, Raszynski A. Acute kidney injury during vancomycin therapy in critically ill children. Pharmacotherapy. 2013;33(6):598-602.

24. Bonazza S, Bresee LC, Kraft T, Ross BC, Dersch-Mills D. Frequency of and risk factors for acute kidney injury associated with vancomycin use in the pediatric intensive care unit. J Pediatr Pharmacol Ther. 2016;21(6):486-93.

25. Menon S, Kirkendall ES, Nguyen H, Goldstein SL. Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months. J Pediatr. 2014;165(3):522-7.e2.

26. Zappitelli M, Moffett BS, Hyder A, Goldstein SL. Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant. 2011;26(1):144-50.

27. Joyce EL, Kane-Gill SL, Fuhrman DY, Kellum JA. Drug-associated acute kidney injury: who’s at risk? Pediatr Nephrol. 2017;32(1):59-69.

28. Rhone ET, Carmody JB, Swanson JR, Charlton JR. Nephrotoxic medication exposure in very low birth weight infants. J Matern Fetal Neonatal Med. 2014;27(14):1465-90.